AptarGroup has announced its acquisition of Nanopharm and Gateway Analytical as “part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.”
The two companies were acquired by Aptar for a total of approximately $50 million. Both will continue to operate as independent units, similar to OINDP testing specialist Next Breath, which was acquired by Aptar in 2008.
Nanopharm offers development and analytical services for a variety of inhalation products. In July 2018, the company announced that it was partnering with US-based Sciarra Laboratories to provide CDMO services for MDIs. Nanopharm employs 37 people at its headquarters in Newport, UK.
Gateway Analytical offers a number of pharmaceutical analytical services, including ingredient specific particle sizing, foreign particulate identification, and agglomerate analysis for OINDPs. In 2016, Gateway moved to a 17,000 sq ft GMP facility in Gibsonia, PA, USA, where it employs 18 analysts.
Aptar Pharma President Gael Touya said, “We are delighted to welcome the talented teams of Nanopharm and Gateway and their customers to Aptar Pharma. Their expertise and capabilities will deepen our current range of services offered to customers who are developing and testing inhaled and injected medicines. This enables us to participate in a broader spectrum of the pre-clinical, clinical trial and market launch phases of drug development.”
Nanopharm Founder and Chief Scientific Officer Robert Price commented, “In Aptar we have found the ideal partner to continue the successful growth of Nanopharm. Aptar Group is perfectly positioned to support the development of our science driven, solution-oriented services for inhalation and nasal drug products. This exciting new chapter in our development will allow us to deliver yet more as we leverage Aptar’s expertise and infrastructure to better serve our highly-valued clients.”
Nanopharm CEO Jag Shur added, “Our decision to join forces with Aptar Group has been made very carefully indeed. This synergistic partnership and shared commitment to scientific excellence, will enable us to better serve our clients by offering a broader spectrum of innovative solutions and enhance our level of technical services going forward. The future of Nanopharm as part of the Aptar Group is very exciting indeed.”
Gateway Analytical President David Exline said, “We are delighted to join Aptar Pharma, a leader in the field of drug delivery devices and value-added services to their pharmaceutical customers. With our combined resources and teams we can offer customers a broader range of specialized and differentiated products and services, and maintain the superior level of service and quality they’ve been receiving from Gateway Analytical. In addition, our worldwide reach will be significantly enhanced with the leadership of Aptar Pharma.”
Read the Aptar Pharma press release.
